α-glucosidase (CHO) (genzyme)

Current Opinion in Investigational Drugs

Volumn 5, Issue 10, 2004, Pages 1101-1110

  Lachmann, Robin H ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE; RECOMBINANT PROTEIN;

ANIMAL; CHEMISTRY; CLINICAL TRIAL; ENZYMOLOGY; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; TREATMENT OUTCOME;

ALPHA-GLUCOSIDASES; ANIMALS; CLINICAL TRIALS; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TREATMENT OUTCOME;

EID: 16644363403     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. 292936 Duke researchers develop first treatment for rare muscle disease. Duke University PRESS RELEASE 1998 February 14
2. 360936 Pharming Group NV reports fiscal 1999 year end results. Pharming Group NV PRESS RELEASE 2000 March 27
3. 363626 Genzyme General obtains rights to Pompe disease therapy from Synpac. Genzyme General PRESS RELEASE 2000 April 19
4. 363813 Genzyme General reports strong first-quarter EPS and revenue growth. Genzyme General PRESS RELEASE 2000 April 20
5. 363920 Duke obtains FDA designation for Pompe disease therapy. Duke University Medical Center PRESS RELEASE 1997 September 03
6. 384975 Genzyme and Pharming present Pompe disease trial results. Genzyme General PRESS RELEASE 2000 October 05
7. 399330 Genzyme General provides 2001 financial guidance. Genzyme General PRESS RELEASE 2001 February 16
8. 402582 Positive results for Genzyme and Pharming's Pompe disease therapy. Genzyme General PRESS RELEASE 2001 March 20
9. 406931 Pharming Group NV reports results Q1 2001. Pharming Group NV PRESS RELEASE 2001 April 23
10. 420340 Genzyme muscles Pharming out of Pompase program. Genzyme Corp PRESS RELEASE 2001 August 27
11. 420656 Drug development pipeline: Genzyme and Pharming. Genzyme General COMPANY COMMUNICATION 2001 August 30
12. 451138 Annual report 2001: Genzyme Corp (Genzyme General, Genzyme Molecular Oncology and Genzyme Biosurgery). Genzyme Corp ANNUAL REPORT 2002 March 25
13. 467424 Recombinant human α-glucosidase from rabbit milk in Pompe patients. Van den Hout H, Reuser AJ, Vulto AG, Loonen MC, Cromme-Dijkhuis A, Van der Ploeg AT LANCET 2000 356 9227 397-398
14. 467435 Targeted disruption of the acid α-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. Raben N, Nagaraju K, Lee E, Kessler P, Byrne B, Lee L, LaMarca M, King C, Ward J, Sauer B, Plotz P J BIOL CHEM 1998 273 30 19086-19092
15. 478321 Genzyme General provides 2003 financial guidance. Genzyme General PRESS RELEASE 2003 February 04
16. 482593 Genzyme starts enlisting patients in Pompe disease trial. Genzyme General PRESS RELEASE 2003 March 19
17. 491224 Genzyme begins patient enrollment in Pompe study. Genzyme Corp PRESS RELEASE 2003 May 29
18. 504485 Genzyme expands Myozyme development program for Pompe disease. Genzyme Corp PRESS RELEASE 2003 September 10
19. 507491 Clinical and metabolic correction of Pompe disease by enzyme therapy in acid maltase-deficient quail. Kikuchi T, Yang HW, Pennybacker M, Ichihara N, Mizutani M, Van Hove JL, Chen YT J CLIN INVEST 1998 101 4 827-833
20. 507492 Recombinant human acid α-glucosidase corrects acid α-glucosidase-deficient human fibroblasts, quail fibroblasts, and quail myoblasts. Yang HW, Kikuchi T, Hagiwara Y, Mizutani M, Chen YT, Van Hove JL PEDIATR RES 1998 43 3 374-380
21. 507495 High-level production of recombinant human lysosomal acid α-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease. Van Hove JL, Yang HW, Wu JY, Brady RO, Chen YT PROC NATL ACAD SCI USA 1996 93 1 65-70
22. 507500 Enzyme replacement therapy with recombinant human acid α-glucosidase (rhGAA) in infantile Pompe disease (IPD): Results from a phase 2 study. Kishnani P, Voit T, Nicolino M, Tsai C, Herman G, Waterson J, Rogers RC, Chen Y GENETICS MED 2003 5 3 209
23. 507507 Administration of recombinant human acid α-glucosidase (rh-GAA) to patients with infantile Pompe disease results in a rapid decrease in left ventricular hypertrophy (LVH): Preliminary results from a phase 2 study. Levine JC, Colan S, Kishnani P, Amalfitano A, Tsai CH, Herman G, Waterson J, Rogers RC, Yong F, Chen YT CIRCULATION 2002 106 19 Suppl 521
24. 525075 Genzyme to expand presence in oncology through licensing deals in 2004. FDC REPORTS PINK SHEET 2004 66 8 24
25. 548227 A biochemical comparison of recombinant human acid α-glucosidase expressed in CHO cells and transgenic rabbits. Lee KL, Baker-Malcolm J, Albee K, Edmunds T, Mattaliano R AM J HUM GENET 2003 73 5 Suppl 627
26. 548228 An in vivo comparison of the efficacy of acid α-glucosidase produced in CHO cells and transgenic rabbits. McVie-Wylie A, Rogers C, Gotschall R, Thurberg B, Canfield W, Mattaliano R, Andrews L AM J HUM GENET 2003 73 5 Suppl 623
27. 550983 Enzyme replacement therapy: Conception, chaos and culmination. Brady RO PHILOS TRANS R SOC LOND BIOL 2003 358 1433 915-919
28. 550985 Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. Martiniuk F, Chen A, Mack A, Arvanitopoulos E, Chen Y, Rom WN, Codd WJ, Hanna B, Alcabes P, Raben N, Plotz P AM J MED GENET 1998 79 1 69-72
29. 550987 Primary structure and processing of lysosomal α-glucosidase; homology with the intestinal sucrase-isomaltase complex. Hoefsloot LH, Hoogeveen-Westerveld M, Kroos MA, van Beeumen J, Reuser AJ, Oostra BA EMBO J 1988 7 6 1697-1704
30. 550988 Generalised glycogenosis in Brahman cattle. O'Sullivan BM, Healy PJ, Fraser IR, Nieper RE, Whittle RJ, Sewell CA AUST VET J 1981 57 5 227-229
31. 550989 Bovine generalized glycogenosis type II: A clinico-pathological study. Edwards JR, Richards RB BR VET J 1979 135 4 338-348
32. 551017 Glycogenosis II in Japanese quails. Murakami H, Takagi A, Nanaka S, Ishiura S, Sugita H JIKKEN DOBUTSU 1980 29 4 475-478
33. 551066 Enzyme replacement therapy in the mouse model of Pompe disease. Raben N, Danon M, Gilbert AL, Dwivedi S, Collins B, Thurberg BL, Mattaliano RJ, Nagaraju K, Plotz PH MOL GENET METAB 2003 80 1-2 159-169
34. 551084 Long-term intravenous treatment of Pompe disease with recombinant human α-glucosidase from milk. Van den Hout JM, Kamphoven JH, Winkel LP, Arts WF, De Klerk JB, Loonen MC, Vulto AG, Cromme-Dijkhuis A, Weisglas-Kuperus N, Hop W, Van Hirtum H et al PEDIATRICS 2004 113 5 E448-E457
35. 551088 Induction of tolerance to a recombinant human enzyme, acid α-glucosidase, in enzyme deficient knockout mice. Raben N, Nagaraju K, Lee A, Lu N, Rivera Y, Jatkar T, Hopwood JJ, Plotz PH TRANSGENIC RES 2003 12 2 171-178
36. 551089 Enzyme replacement therapy in late-onset Pompe's disease: A three-year follow-up. Winkel LP, Van den Hout JM, Kamphoven JH, Disseldorp JA, Remmerswaal M, Arts WF, Loonen MC, Vulto AG, Van Doorn PA, De Jong G, Hop W et al ANN NEUROL 2004 55 4 495-502.
37. 551090 Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy. Winkel LP, Kamphoven JH, van den Hout HJ, Severijnen LA, van Doorn PA, Reuser AJ, Van der Ploeg AT MUSCLE NERV 2003 27 6 743-751
38. 555601 Recombinant human acid α-glucosidase enzyme therapy for infantile glycogen storage disease type II: Results of a phase I/II clinical trial. Amalfitano A, Bengur AR, Morse RP, Majure JM, Case LE, Veerling DL, Mackey J, Kishnani P, Smith W, McVie-Wylie A, Sullivan JA et al GENETICS MED 2001 3 2 132-138
39. 555604 Glycogen storage disease type II: Birth prevalence agrees with predicted genotype frequency. Ausems MG, Ten Berg K, Kroos MA, Van Diggelen OP, Wevers RA, Poorthuis BJ, Niezen-Koning KE, Van Der Ploeg AT, Beemer FA, Reuser AJ, Sandkuijl LA, Wokke JH COMMUNITY GENET 1999 2 2 91-96
40. 557328 Glycogen storage disease type II: Acid α-glucosidase (acid maltase) deficiency. Hirschhorn R In: THE METABOLIC AND MOLECULAR BASIS OF INHERITED DISEASE Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill Inc, New York, NY, USA 1995 2443-2464
41. 557329 Hepatic lysosomes in Pompe's disease: Disappearance during glucosidase administration. Hug G, Schubert WK J CLIN INVEST 1967 46 1073
42. 557332 Administration of a mixture of fungal glucosidases to a patient with type II glycogenosis (Pompe's disease). Lauer RM, Mascarinas T, Racela AS, Diehl AM, Brown BI PEDIATRICS 1968 42 4 672-676
43. 557339 Enzyme replacement in Pompe disease: An attempt with purified human acid α-glucosidase. de Barsy T, Jacquemin P, Van Hoof F, Hers HG BIRTH DEFECTS ORIG ARTIC SER 1973 9 2 184-190
44. 557341 Enzyme replacement in Pompe disease with an α-glucosidase-low density lipoprotein complex. Williams JC, Murray AK BIRTH DEFECTS ORIG ARTIC SER 1980 16 1 415-423
45. 557347 Bovine generalized glycogenosis. Richards RB, Edwards RD, Cook RR, White RR NEUROBIOL 1977 3 45-56
46. 557351 Infantile and late onset form of generalised glycogenosis type II in cattle. Howell JM, Dorling PR, Cook RD, Robinson WF, Bradley S, Gawthorne JM J PATHOL 1981 134 4 267-277
47. 557352 Developmental study of α-glucosidases in Japanese quails with acid maltase deficiency. Usuki F, Ishiura S, Sugita H MUSCLE NERVE 1986 9 6 537-543
48. 557355 Acid maltase deficiency in the Japanese quail; early morphological event in skeletal muscle. Higuchi I, Nonaka I, Usuki F, Ishiura S, Sugita H ACTA NEUROL BELG 1987 73 1 32-37
49. 557357 Japanese quail and human acid maltase deficiency: A comparative study. Fujita T, Nonaka I, Sugita H BRAIN DEVELOP 1991 13 4 247-255
50. 557359 Sequence of the cDNA and 5'-flanking region for human acid α-glucosidase, detection of an intron in the 5' untranslated leader sequence, definition of 18-bp polymorphisms, and differences with previous cDNA and amino acid sequences. Martiniuk F, Mehler M, Tzall S, Meredith G, Hirschhorn R DNA CELL BIOL 1990 9 2 85-94
51. 557362 Expression and routeing of human lysosomal α-glucosidase in transiently transfected mammalian cells. Hoefsloot LH, Willemsen R, Kroos MA, Hoogeveen-Westerveld M, Hermans MM, Van der Ploeg AT, Oostra BA, Reuser AJ BIOCHEM J 1990 272 2 485-492
52. 557364 Structural and functional changes of lysosomal acid α-glucosidase during intracellular transport and maturation. Wisselaar HA, Kroos MA, Hermans MM, van Beeumen J, Reuser AJ J BIOL CHEM 1993 268 3 2223-2231
53. 557367 Lysosomes in type II glycogenosis. Changes during administration of extract from Aspergillus niger. Hug G, Schubert WK J CELL BIOL 1967 35 1 C1-C6
54. 557369 Uptake and stability of human and bovine acid α-glucosidase in cultured fibroblasts and skeletal muscle cells from glycogenosis type II patients. Reuser AJ, Kroos MA, Ponne NJ, Wolterman RA, Loonen MC, Busch HF, Visser WJ, Bolhuis PA EXP CELL RES 1984 155 1 178-189
55. 557370 Prospect for enzyme therapy in glycogenosis II variants: A study on cultured muscle cells. Van der Ploeg AT, Bolhuis PA, Wolterman RA, Visser JW, Loonen MC, Busch HF, Reuser AJ J NEUROL 1988 235 7 392-396
56. 557374 Intravenous administration of phosphorylated acid α-glucosidase leads to uptake of enzyme in heart and skeletal muscle of mice. Van der Ploeg AT, Kroos MA, Willemsen R, Brons NH, Reuser AJ J CLIN INVEST 1991 87 2 513-518
57. 557377Isolation and characterisation of a recombinant, precursor form of lysosomal acid α-glucosidase. Fuller M, Van der Ploeg A, Reuser AJ, Anson DS, Hopwood JJ EUR J BIOCHEM 1995 234 3 903-909
58. 557378 Recombinant human acid α-glucosidase: High level production in mouse milk, biochemical characteristics, correction of enzyme deficiency in GSDII KO mice. Bijvoet AG, Kroos MA, Pieper FR, Van der Vliet M, De Boer HA, Van der Ploeg AT, Verbeet MP, Reuser AJ HUM MOL GENET 1998 7 11 1815-1824
59. 557380 Human acid α-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II. Bijvoet AG, Van Hirtum H, Kroos MA, Van de Kamp EH, Schoneveld O, Visser P, Brakenhoff JP, Weggeman M, van Corven EJ, Van der Ploeg AT, Reuser AJ HUM MOL GENET 1999 8 12 2145-2153
60. 557398 Isolation and characterization of a precursor form of lysosomal α-glucosidase from human urine. Oude Elferink RP, Brouwer-Kelder EM, Surya I, Strijland A, Kroos M, Reuser AJ, Tager JM EUR J BIOCHEM 1984 139 4 489-495
61. 557402 Quantitation of Mr 46000 and Mr 300000 mannose 6-phosphate receptors in human cells and tissues. Wenk J, Hille A, von Figura K BIOCHEM INT 1991 23 4 723-732
62. 557403 Expression of the insulin-like growth factor-II/mannose-6- phosphate receptor in multiple human tissues during fetal life and early infancy. Funk B, Kessler U, Eisenmenger W, Hansmann A, Kolb HJ, Kiess W J CLIN ENDOCRINOL METAB 1992 75 2 424-431
63. 557404 Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: Induction of humoral tolerance in seroconverted patients after repeat administration. Rosenberg M, Kingma W, Fitzpatrick MA, Richards SM BLOOD 1993 93 6 2081-2088
64. 557593 Acid maltase deficiency (type II glycogenosis). Morphological and biochemical study of a childhood phenotype. Martin JJ, De Barsy T, De Schrijver, Leroy JG, Palladini G J NEUROL SCI 1976 30 1 155-166
65. 557594 Pompe's disease: An inborn lysosomal disorder with storage of glycogen. A study of brain and striated muscle. Martin JJ, de Barsy T, van Hoof F, Palladini G ACTA NEUROPATHOL 1973 23 3 229-244
66. 557598 Determination of acid α-glucosidase protein: Evaluation as a screening marker for Pompe disease and other lysosomal storage disorders. Umapathysivam K, Whittle AM, Ranieri E, Bindloss C, Ravenscroft EM, van Diggelen OP, Hopwood JJ, Meikle PJ CLIN CHEM 2000 46 9 1318-1325
67. 557600 Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening. Li Y, Scott CR, Chamoles NA, Ghavami A, Pinto BM, Turecek F, Gelb MH CLIN CHEM 2004 doi:10.1373/ clinchem.2004.035907
68. 558193 CSFB Biotech Beat. Augustine ME, Troyer RL, Park MS, Biegert LR CREDIT SUISSE FIRST BOSTON 2004 July 19
69. 558196 Genzyme (GENZ). Genz: Better than expected FY04 outlook; revising. Wang E, Pandya S, Rapaport R CITIGROUP SMITH BARNEY 2004 February 19
70. 558320 Genzyme Corporation. US BANCORP PIPER JAFFRAY INC 2004 August 25